Empowering Patients' Lung Cancer Screening Uptake (Empower LCS/Call+)

Conditions

• Early Detection of Cancer
• Lung Cancer Screening
• Lung Neoplasms
• Smoking ( Cigarette)

Eligibility Criteria

Sex

ALL

Age

50 Years - 80 Years

Healthy Volunteers

Not accepted

Interventions

• Empower LCS — BEHAVIORAL
  Empower LCS consists of (1) a lung cancer screening decision aid, (2) primary care provider notification of patients' eligibility for lung cancer screening, (3) patient text reminders to discuss lung cancer screening with their primary care provider, and (4) tailored support materials including financial education and national/local resources for patients who screen positive for health-related social needs.
• Call+ Telephone Navigation — BEHAVIORAL
  Participants who do not complete lung cancer screening by approximately 4 months after randomization will receive the Call+, a telephone-based navigation intervention delivered by a lay navigator to identify and address barriers to screening, facilitate scheduling, and connect participants with available resources.
• Usual Care — OTHER
  Usual care
• Education — OTHER
  One-page educational material about benefits and risks of lung cancer screening

Study Details

Lung cancer screening (LCS) with low-dose computed tomography (LDCT) can reduce the risk of dying from lung cancer, but many people who are eligible for screening do not receive it. The purpose of the Empower LCS/Call+ study is to evaluate new strategies to improve lung cancer screening among adults who are eligible for screening based on current U.S. Preventive Services Task Force (USPSTF) guidelines. This pilot randomized controlled trial will enroll approximately 80 participants from UC Irvine Health and Emory Healthcare. Participants will be randomly assigned to receive either enhanced usual care or the Empower LCS/Call+ intervention. The intervention includes educational materials, reminders for patients and primary care providers, and information about financial and community resources when appropriate. Participants who do not complete lung cancer screening after the initial intervention may receive additional telephone-based navigation through the Call+ program to help identify and address barriers to screening and help with scheduling. Participants will complete a baseline survey and follow-up surveys at 4 and 8 months, and researchers will review electronic health record information to determine whether lung cancer screening was discussed, ordered, and completed. Some participants will also be invited to complete a one-time interview about their experiences with the study. The results of this study will help determine the feasibility, acceptability, and preliminary effectiveness of the Empower LCS/Call+ intervention and will inform future efforts to improve equitable access to lung cancer screening.

Key Dates

First listed

Jul 17, 2026

Start date

Sep 1, 2026

Status verified

Jul 2026

Primary completion

Aug 31, 2028

Completion

Dec 31, 2028

Study Design

Enrollment

80 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

HEALTH_SERVICES_RESEARCH

Arms

• Active Comparator: Enhanced Usual Care
  Usual care + educational brochure
• Experimental: Empower LCS/Call+
  Empower LCS with Call+ offered to non-responders

Primary Outcome Measure

Completion of lung cancer screening with low-dose computed tomography (LDCT) [ Time Frame: 4 months after randomization ]

Central Contacts

• Gelareh Sadigh, MD
  (714) 456-3610
  [email protected]

Locations (14)

Find similar trials in Anaheim, CA

Related Studies

• Caris Biorepository Research Protocol
  Recruiting · Caris Science, Inc. · Mobile, Alabama
• Evaluating the Impact of CONNECT in a Multilingual Population
  Not Yet Recruiting · University of California, San Francisco · San Francisco, California
• Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer
  PHASE2 · Recruiting · Pfizer · Duarte, California
• Molecular Analysis of Oncogenes and Resistance Mechanisms in Lung Cancer
  Recruiting · University of Colorado, Denver · Aurora, Colorado